Skip to main content
Clinical Trials/CTRI/2022/11/047692
CTRI/2022/11/047692
Not yet recruiting
Phase 4

Comparison of therapeutic efficacy and safety of two concentrations of intra-lesional triamcinolone acetonide in patchy alopecia areata of the scalp: an open label randomized trial

I0 sites0 target enrollmentTBD

Overview

Phase
Phase 4
Intervention
Not specified
Conditions
Health Condition 1: L639- Alopecia areata, unspecified
Sponsor
I
Status
Not yet recruiting
Last Updated
3 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
3 years ago
Study Type
Interventional

Investigators

Sponsor
I

Eligibility Criteria

Inclusion Criteria

  • 1\.Patients of both sexes(males and females), aged \>13 years with AA,
  • 2\.Patients having AA on the scalp with \<50% involvement.
  • 3\.Patients who had not taken any form of treatment in the last 8 weeks.
  • 4\.Patients who are willing to sign the written consent form before participating in the study

Exclusion Criteria

  • 1\.Patients aged \<13 years
  • 2\.Patients with alopecia totalis, alopecia universalis and ophiasis.
  • 3\.Patients having skin diseases affecting the scalp.
  • 4\.Patients with active infection at the local site and with keloidal tendency.
  • 5\.Pregnant or lactating women or immuno\-compromised patients or patients with bleeding or coagulation disorders

Outcomes

Primary Outcomes

Not specified

Similar Trials